As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...
A third dose of the Pfizer/BioNTech COVID-19 vaccine can "strongly" boost protection against the delta variant -- beyond the protection afforded by the standard two doses, suggests new data released ...
Early-stage data from Pfizer’s (NYSE:PFE) experimental breast cancer therapy PF-07248144 boosted the shares of Olema Pharmaceuticals (NASDAQ:OLMA), which is advancing a similar treatment, for the ...
Geometric Mean Titers were comparably high at one month post first and second booster. Pfizer aims to submit marketing applications to the FDA and the European Medicines Agency in 2026, subject to ...
Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown efficacy in immunocompromised adults, the pharma announced Monday. In substudy B of Pfizer’s ongoing Phase 3 MONeT trial, Abrysvo ...
NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...
Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...
The group will discus and vote on whether to recommend Pfizer booster shots. The Food and Drug Administration's independent advisory committee will convene in open session Friday to review the latest ...
NEW YORK - Pfizer on Wednesday shared data about a third dose of its COVID-19 vaccine that suggests it "strongly" boosts protection against the more contagious delta variant of the coronavirus, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback